[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infant-neurodevelopment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infant-neurodevelopment":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100636659","maternal-methyl-nutrient-status-and-infant-neurodevelopment-study-100636659",false,"NCT07568561","Maternal Methyl-Nutrient Status and Infant Neurodevelopment Study","Maternal Methyl-Nutrient Status During Pregnancy and Its Association With Infant Neurodevelopment: Exploring Potential Mechanisms","Inclusion Criteria for Pregnant Women\n\n* Aged 20-45 years\n* Singleton pregnancy\n* Receiving routine prenatal care at the study site and planning to deliver at Far Eastern Memorial Hospital\n\nExclusion Criteria for Pregnant Women\n\n* Diagnosed with major chronic diseases, including renal disease (defined as chronic kidney disease stage 3 or above or history of renal transplantation), liver disease (defined as liver cirrhosis or history of liver transplantation), or malignancy\n* Alcohol consumption during pregnancy\n* Diagnosed with eating disorders or psychiatric conditions that may impair the assessment of nutritional status\n\nInclusion Criteria for Newborns\n\n● Newborns delivered by mothers who participate in this study\n\nExclusion Criteria for Newborns\n\n* Diagnosed with congenital anomalies, epilepsy, or severe brain injury\n* Inability to complete neurodevelopmental assessments at 6 months, 1 year, and 2 years of age at the study site\n* Infants whose mothers are diagnosed with eating disorders or psychiatric conditions that may impair the assessment of nutritional status",true,"ALL","0 Days","45 Years",{"count":21,"type":22},240,"ESTIMATED","2 Years","OBSERVATIONAL","This prospective cohort study examines the relationship between maternal methyl-nutrient status during pregnancy and offspring neurodevelopment. It integrates maternal dietary, biomarker, genetic, and microbiome data and follows children up to 24 months.",[27,28,29,30,31,32,33,34,35],"Infant Neurodevelopment","Nutrition","Methylation","Birth Outcomes","Pregnancy","Dietary Quality","Dietary Intake Assessment","Homocysteine","Trimethylamine N-oxide (TMAO)","RECRUITING","2026-05-27",{"date":39,"type":40},"2026-05-29","ACTUAL",{"date":37,"type":40},{"date":43,"type":22},"2029-01-18",{"name":45,"class":46},"Far Eastern Memorial Hospital","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100630908","phase-2-dexmedetomidine-for-invasive-ventilation-in-the-neonate-100630908","NCT07493785","Dexmedetomidine for Invasive Ventilation In the NEOnate","Double Blind, Multicenter, Randomized, Controlled Trial of Dexmedetomidine vs Placebo in Premature Neonates Receiving Invasive Ventilation","Above mentioned age limits (0 -10 weeks) apply to postnatal age. Inclusion criteria apply to gestational age at birth and postmenstrual age (in weeks).\n\nInclusion Criteria:\n\n* Neonates with a gestational age at birth \\\u003C 32 weeks of gestation and corrected gestational age \\\u003C 32 weeks postmenstrual age\n* Invasively ventilated with an expected or effective duration of ventilation \\> 24 hours at inclusion\n* Under mechanical ventilation since less than 72 hours at inclusion\n* With parental consent\n* Affiliated to or benefiting from a social security system\n\nExclusion Criteria:\n\n* Previous inclusion in this trial\n* Participation in another trial including analgesics or sedatives\n* Ongoing palliative care\n* Administration of dexmedetomidine or another alpha-2 agonist in the 96 previous hours\n* Hemodynamic compromise defined as any of: poor perfusion (increased capillary refill time, oliguria); hypotension defined as a mean blood pressure in mm Hg \\\u003C postmenstrual age in weeks; ongoing inotropic treatment with dopamine or dobutamine ≥ 5 µg\u002Fkg\u002Fmin, or any other inotropic drug at any dose, or need for more than one volume expansion (20 ml\u002Fkg) in the 6 previous hours\n* Pulmonary hypertension requiring pharmacological treatment\n* Heart rate \\\u003C100 bpm\n* Hepatic impairment defined as alanine aminotransferase level \\> 2 x normal upper limit\n* Known contra-indications to dexmedetomidine: hypersensitivity, atrioventricular block, acute cerebrovascular event\n* Hypersensitivity to the active substance or to any of the excipients contained in the medicine","10 Weeks",{"count":56,"type":22},246,"INTERVENTIONAL",[59,60],"PHASE2","PHASE3","Despite the increasing use of non-invasive ventilation, a large majority of premature neonates still receive invasive ventilation during their NICU (neonatal intensive care unit) stay. Invasive ventilation is a unanimous source of discomfort and pain.\n\nAs opposed to the adult and pediatric population, routine use of opioids or midazolam is not recommended in ventilated neonates.\n\nAlthough opioids are the most frequently prescribed analgosedative drugs in ventilated premature neonates, their use is controversial because of the risk of respiratory depression - which can prolong invasive ventilation- and concerns on long-term neurodevelopment.\n\nDexmedetomidine, a selective alpha-2- adrenergic agonist routinely used in the adult ICU (intensive care unit), provides light sedation and some analgesia with no or little respiratory-depression effect. It also has neuroprotective properties after pediatric cardiac surgery and in neonatal animal models. Dexmedetomidine is thus a promising candidate drug in ventilated premature neonates that might reduce the duration of mechanical ventilation and preserve neurodevelopment in this vulnerable population.\n\nThe investigators hypothesize that the use of dexmedetomidine in ventilated premature neonates could decrease the need for opioids, facilitate extubation and thereby preserve long-term neurodevelopmental outcome.",[63,64,65,27,66],"Invasive Ventilation","Infant Pain","Infant Discomfort","Neonatal Respiratory Failure",[68,69,70,71,72,73,74,75],"Neonatology","Invasive mechanical ventilation","Analgesia","Dexmedetomidine","Neurodevelopment","Opioids","Pain","Withdrawal syndrome","NOT_YET_RECRUITING","2026-03-20",{"date":79,"type":40},"2026-03-25",{"date":81,"type":22},"2026-06-01",{"date":83,"type":22},"2034-08-01",{"name":85,"class":46},"Centre Hospitalier Intercommunal Creteil",12]